The company, formed in 2013, aims to provide innovative therapeutic options by administering drugs subcutaneously using a convenient two-component delivery system. By targeting patients with serious medical conditions, ScPharmaceuticals offers a safe and comfortable alternative to intravenous administration, while reducing costs and burdens associated with it. Their pipeline includes products in various stages of development, with a focus on cardiovascular and infectious disease areas. Their lead product, Furoscix, combines a patented formulation of furosemide with a wearable sc2Wear Infusor, providing an effective treatment for edema in heart failure patients.